Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04789096
Title Tucatinib Together With Pembrolizumab and Trastuzumab (TUGETHER)
Acronym TUGETHER
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Breast Cancer Trials, Australia and New Zealand
Indications
Therapies
Age Groups: adult | senior
Covered Countries AUS


No variant requirements are available.